| Prev Close | 4.58 |
| Open | 4.60 |
| Day Low/High | 4.55 / 4.71 |
| 52 Wk Low/High | 4.14 / 7.74 |
| Volume | 448.14K |
| Avg Volume | 881.70K |
| Exchange | NASDAQ |
| Shares Outstanding | 80.22M |
| Market Cap | 379.43M |
| EPS | -0.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Spectrum Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Spectrum Pharmaceuticals, Inc.
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Against Spectrum Pharmaceuticals, Inc. - SPPI
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Spectrum Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Spectrum Pharmaceuticals, Inc.
Levi & Korsinsky, LLP announces that it has commenced an investigation of Spectrum Pharmaceuticals, Inc.
First Week of SPPI May 2017 Options Trading
Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the May 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Spectrum Pharmaceuticals, Inc.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Spectrum Pharmaceuticals, Inc.
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces An Investigation Of Spectrum Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm
Lundin Law PC ( http://lundinlawpc.com/) announces that it is investigating claims against Spectrum Pharmaceuticals, Inc.
Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
Spectrum Pharmaceuticals (SPPI) Stock Slumps on FDA Ruling
An FDA committee said on Wednesday that Spectrum Pharmaceuticals' (SPPI) Qapzola drug for bladder tumors did not show substantial evidence of efficacy.
FDA Advisory Committee Votes That Qapzola™ (apaziquone) Has Not Shown Substantial Evidence Of A Treatment Effect Over Placebo
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.
Spectrum Pharmaceuticals Stock Sees Short Interest Decline 15%
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 1,258,512 share decrease in total short interest for Spectrum Pharmaceuticals Inc , to 7,187,253, a decrease of 14.90% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
October 21st Options Now Available For Spectrum Pharmaceuticals (SPPI)
Investors in Spectrum Pharmaceuticals Inc saw new options become available today, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new October 21st contracts and identified the following put contract of particular interest.
RSI Alert: Spectrum Pharmaceuticals (SPPI) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results And Pipeline Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...
Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference And Webcast
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...
Spectrum Pharmaceuticals Becomes Oversold (SPPI)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate Injection) ANDA Patent Litigation
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that it has settled its...
Spectrum Pharmaceuticals To Present Corporate Update At The Cantor Fitzgerald's 2nd Annual Healthcare Conference On July 13th
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...
Spectrum Pharmaceuticals Enters Oversold Territory (SPPI)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
First Week of February 2017 Options Trading For Spectrum Pharmaceuticals (SPPI)
Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2016 Healthcare Conference On June 8th
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...
Spectrum Pharmaceuticals Highlights An Oral Presentation On Apaziquone At The 2016 Annual Meeting Of The American Urological Association Education And Research Inc. (AUA) In San Diego, California, May 6-10, 2016
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today presentations of clinical...
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results And Pipeline Update
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results...
Spectrum Pharmaceuticals To Present Corporate Update At The Bank Of America Merrill Lynch 2016 Healthcare Conference On May 10th
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...
Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference And Webcast
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...
FDA Grants Orphan Drug Exclusivity To EVOMELA™ (melphalan) For Injection, Indicated For Multiple Myeloma
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.
